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expression of SHP1, indicating a possible role in the tumor formation 
in lung cancer and pointing to novel therapeutic strategies.
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Background: Tumor-associated extracellular matrix molecules are 
isoforms of proteins with a wide distribution in normal adult tissues, 
such as ﬁbronectin and tenascin. Large Tenascin-C isoforms are present 
in almost all normal adult tissues but are upregulated in fetal, regenerat-
ing, and neoplastic tissues. In this study we investigated the expression 
of three tenascin isoforms in tumor tissue samples from lung cancer 
patients to evaluate the diagnostic and therapeutic value for clinical 
applications.
Methods: In total, 35 corresponding tissue samples (tumor and normal 
lung tissue of the same patient) have been analyzed by immunohis-
tochemistry using three different human monoclonal antibodies to 
domains A1 (F16), C (G11) and D (P12). All tumor specimens have 
been non-small cell lung cancer types.
Results: Three isoforms G11, F16 and P12 have exhibited a very 
intense staining of different histological types of lung cancer. More 
than 80% of squamous cell carcinomas, adenocarcinomas and large cell 
carcinoma samples have been positively stained. None of the corre-
sponding normal lung tissue specimens showed an expression of either 
tenascin domains.
Conclusions: The results show that tenascin-C isoforms are highly 
expressed around the neovasculature and in the stroma of the majority 
of non-small cell lung cancers but is undetectable in the normal lung 
tissue. Therefore these isoforms could represent valuable candidates for 
the development of antibody based biopharmaceuticals for the treat-
ment of lung cancer.
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The Eph proteins compromise a family of receptor tyrosine kinases that 
are involved in cell-cell interactions, morphogenesis and angiogenesis. 
Especially, EphA2 receptor has been implicated in neovascularization 
of various cancers with its ligand, ephrin A1. How interaction between 
EphA2 and ephrin A1 was concerned with intracellular signaling 
pathway remains to be controversial. As for cancer, other investigations 
has demonstrated that EphA2 is regulated by p53-family proteins, E-
cadherin and ras gene. Especially, in recent reports EphA2 in non-small 
lung cancer may provide a promising marker to predict patients with 
brain metastasis.
Purpose: The purpose of this study is to determine whether EphA2 
correlates with tumor progression, angiogenesis, p53 and E-cadherin 
mediated adhesion in non-small lung cancer. 
Experimental Design: We evaluated EphA2 and ephrin A1 us-
ing immunohistochemistry in 41 cases (I:14, III:27) with long-term 
follow up. Additionally the relationship among EphA2 expression, 
MVD(microvascular density), clinicopathological parameters, and E-
cadherin expression was assessed. 
Results: EphA2 expression was identiﬁed in 28 cases(68.3%). Stage I 
cases displayed signiﬁcantly lower levels than stage III cases(p=0.017). 
Survival curve determined by the Kaplan Meier method demonstrated 
that strong immunoreactivity for EphA2 was associated with overall 
survival (p=0.028). The MVD in EphA2 positve group was signiﬁcant-
ly higher than that in EphA2 negative group (p=0.006). In imuunohis-
tochemical study EphA2 expression was related to loss of E-cadherin 
(p=0.041), but not to p53 on serial sections.
Conclusions: EphA2 expression was associated with tumor progres-
sion, angiogenesis and loss of E-cadherin. 
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Somatic mutations in epidermal growth factor receptor (EGFR) 
tyrosine kinase domain predicts the response to EGFR tyrosine kinase 
inhibitor (TKI) in non-small cell lung cancer (NSCLC). The emergence 
of acquired resistance to EGFR TKI has been recently described in 
patients whose tumor initially responded to geﬁtinib. Lapatinib is a 
dual inhibitor of ErbB1 (EGFR) and ErbB2 (HER-2) tyrosine kinases 
and has shown promising efﬁcacy in HER-2 overexpressing breast 
cancer. However, its therapeutic role is not fully studied in NSCLC. 
Here we report that lapatinib enhances cytotoxicity against geﬁtinib-
resistant NSCLC by blocking active heterodimerization of EGFR and 
HER-2. We identiﬁed a secondary T790M mutation in a NSCLC tumor 
with a geﬁtinib-sensitive L858R mutation that eventually progressed 
after initial response. Acquired T790M mutation conferred resistance 
to L858R mutant cells sensitive to geﬁtinib. Of the various molecules 
downstream of EGFR, signal transduction and activator of transcription 
3 (Stat3) signaling was continuously activated in L858R/T790M cells, 
and the inhibition of Stat3 suppressed geﬁtinib-resistant cell growth. 
As for Stat3 inhibition, we found that lapatinib inactivated Stat3 and 
inhibited cell growth in geﬁtinib-resistant NSCLC. Finally, lapatinib 
was also found to block the heterodimerization of EGFR and HER-2, 
and this led to the inactivation of Stat3 in geﬁtinib-resistant T790M 
cells, whereas the active heterodimerization of EGFR and HER-2 was 
maintained when these cells were treated with geﬁtinib. Taken together, 
our data suggest that lapatinib may overcome geﬁtinib resistance in 
NSCLC. A clinical investigation of the use of lapatinib in geﬁtinib-re-
sistant NSCLC is strongly warranted.
